Navigation Links
Positive Clinical Data for TASQ - Active Biotech's Novel Treatment,of Prostate Cancer

LUND, Sweden, March, 9, 2007-Active Biotech (ACTI.ST), today announced new positive clinical data from the Phase Ib study of TASQ, for the treatment of prostate cancer.

By step-wise dose escalation, a safe dose of 1 mg/day of TASQ was achieved, which corresponds to a doubling of the previously reported maximum tolerated dose (MTD) level of 0.5 mg/day. This means that a step-wise intra-patient dose-escalation enables a dose of 1 mg/day to be administered in future clinical trials.

"These new results confirm and reinforce earlier results obtained at a lower dose level. We now have a very complete data set that constitute a solid base to move into Phase II clinical trials", said Sven Andréasson, President and CEO of Active Biotech.

The ongoing 10-week study comprises patients with so called hormone-refractory prostate cancer. This is an advanced stage of prostate cancer where the tumor cells no longer respond to hormone treatment. All patients entering the study had rising serum levels of Prostate Specific Antigen (PSA), which is a surrogate marker for tumor progression.

PSA measurements were recorded and PSA velocity (PSAV) was calculated after 28 days of treatment. Five out of six patients had a >50% decrease in PSA velocity compared to prior treatment. Three of these five patients exhibited a decrease in absolute PSA levels.

The study is being performed at the urological clinics at the University Hospitals in Lund, Malmö and Uppsala, Sweden.

The objective of the TASQ project is to develop a pharmaceutical product that can be administered orally for the long-term treatment of prostate cancer. Phase II studies are scheduled to start during 2007. The Medical Products Agency has approved on the new MTD to be used in the continued clinical program of TASQ.

The pharmaceutical market for prostate cancer is estimated at more than USD 3 billion a year. Prostat e cancer is the most common form of cancer among men. The incidence is strongly age-related and is unusual before age 50. In 2006, 2.2 million new cases were estimated to have been diagnosed in the US alone.

Lund, March 9, 2007

Active Biotech AB (publ) Sven Andréasson President and CEO

For further information, please contact: Sven Andréasson, President and CEO, tel. +46 46 19 20 49 Tomas Leanderson, Chief Scientific Officer, tel +46 46 19 20 95 Cecilia Hofvander, Manager Corporate Communication, tel. +46 46 19 11 22

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics.

Active Biotech AB ( 556223-9227) P.O. Box 724, SE-220 07 Lund, Sweden Tel +46 46-19 20 00 Fax +46 46-19 20 50


Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):